Duality Advisers’s Rocket Pharmaceuticals RCKT Stock Holding History

Duality Advisers’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-48,943	Closed	-$1.07M	–	800
2021 Q4	$1.07M	Buy	48,943 +8,180	+20%	+$223K	0.12%	280
2021 Q3	$1.22M	Buy	+40,763	New	+$1.48M	0.09%	317
2021 Q2	–	Sell	-23,589	Closed	-$1.05M	–	706
2021 Q1	$1.05M	Buy	+23,589	New	+$1.3M	0.09%	343
2020 Q4	–	Sell	-10,240	Closed	-$234K	–	699
2020 Q3	$234K	Buy	+10,240	New	+$252K	0.01%	547

Other funds holding RCKT

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Duality Advisers's RCKT Position: Q1 2022 in Review

Duality Advisers sold out of Rocket Pharmaceuticals (RCKT) in Q1 2022, closing a stake of 48,943 shares — an estimated $1.07M sold.

Duality Advisers first reported a position in RCKT in Q3 2020 and held it in 4 quarters. The position peaked at $1.22M in Q3 2021. 149 funds tracked by Wall St. Rank hold RCKT as of Q1 2022.

Duality Advisers reported no remaining Rocket Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Duality Advisers sold 48,943 Rocket Pharmaceuticals shares in Q1 2022, an estimated $1.07M.
Duality Advisers first reported a position in Rocket Pharmaceuticals in Q3 2020 and held it in 4 quarters.
Duality Advisers's Rocket Pharmaceuticals position peaked at $1.22M in Q3 2021.
149 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2022.

Based on Duality Advisers's 13F filing for Q1 2022, filed 9 May 2022.